TY  - JOUR
AU  - Galldiks, Norbert
AU  - Kaufmann, Timothy J
AU  - Vollmuth, Philipp
AU  - Lohmann, Philipp
AU  - Smits, Marion
AU  - Veronesi, Michael C
AU  - Langen, Karl-Josef
AU  - Rudá, Roberta
AU  - Albert, Nathalie L
AU  - Hattingen, Elke
AU  - Law, Ian
AU  - Hutterer, Markus
AU  - Soffietti, Riccardo
AU  - Vogelbaum, Michael A
AU  - Wen, Patrick Y
AU  - Weller, Michael
AU  - Tonn, Joerg-Christian
TI  - Challenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group
JO  - Neuro-Oncology
VL  - 26
IS  - 7
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - FZJ-2024-01908
SP  - 1181-1194
PY  - 2024
AB  - Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
LB  - PUB:(DE-HGF)16
C6  - 38466087
UR  - <Go to ISI:>//WOS:001196533900001
DO  - DOI:10.1093/neuonc/noae049
UR  - https://juser.fz-juelich.de/record/1024009
ER  -